Efficacy of Ustekinumab Against Spondyloarthritis Associated with Crohn's Disease: A Case Report and Review of the Literature.

IF 1.7 Q3 RHEUMATOLOGY
Open Access Rheumatology-Research and Reviews Pub Date : 2020-07-29 eCollection Date: 2020-01-01 DOI:10.2147/OARRR.S263259
Satohiro Matsumoto, Keita Matsumoto, Hiromu Takaya, Haruka Otake, Hirosato Mashima
{"title":"Efficacy of Ustekinumab Against Spondyloarthritis Associated with Crohn's Disease: A Case Report and Review of the Literature.","authors":"Satohiro Matsumoto,&nbsp;Keita Matsumoto,&nbsp;Hiromu Takaya,&nbsp;Haruka Otake,&nbsp;Hirosato Mashima","doi":"10.2147/OARRR.S263259","DOIUrl":null,"url":null,"abstract":"<p><p>Spondyloarthritis (SpA) is a known extraintestinal complication in inflammatory bowel disease (IBD). However, since the prevalence of SpA is lower in Japan than in Europe, some patients may be inaccurately diagnosed and treated. Although non-steroidal anti-inflammatory drugs (NSAIDs) remain the mainstay treatment for IBD-related SpA, anti-tumor necrosis factor-α antibody and ustekinumab have demonstrated efficacy in patients with SpA refractory to NSAIDs. We report here a case of Crohn's disease with SpA, as an extraintestinal manifestation, in which ustekinumab proved extremely effective, not only for alleviating the arthritis but also against skin manifestations and scleritis. Only a few studies have documented the therapeutic effects of ustekinumab against SpA associated with IBD; therefore, its efficacy remains unclear.</p>","PeriodicalId":45545,"journal":{"name":"Open Access Rheumatology-Research and Reviews","volume":"12 ","pages":"133-137"},"PeriodicalIF":1.7000,"publicationDate":"2020-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OARRR.S263259","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Access Rheumatology-Research and Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OARRR.S263259","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 4

Abstract

Spondyloarthritis (SpA) is a known extraintestinal complication in inflammatory bowel disease (IBD). However, since the prevalence of SpA is lower in Japan than in Europe, some patients may be inaccurately diagnosed and treated. Although non-steroidal anti-inflammatory drugs (NSAIDs) remain the mainstay treatment for IBD-related SpA, anti-tumor necrosis factor-α antibody and ustekinumab have demonstrated efficacy in patients with SpA refractory to NSAIDs. We report here a case of Crohn's disease with SpA, as an extraintestinal manifestation, in which ustekinumab proved extremely effective, not only for alleviating the arthritis but also against skin manifestations and scleritis. Only a few studies have documented the therapeutic effects of ustekinumab against SpA associated with IBD; therefore, its efficacy remains unclear.

Abstract Image

Abstract Image

Abstract Image

Ustekinumab治疗伴有克罗恩病的脊椎关节炎的疗效:1例报告和文献回顾
脊椎关节炎(SpA)是炎症性肠病(IBD)中一种已知的肠外并发症。然而,由于SpA在日本的患病率低于欧洲,一些患者可能被不准确地诊断和治疗。尽管非甾体抗炎药(NSAIDs)仍然是ibd相关SpA的主要治疗方法,抗肿瘤坏死因子-α抗体和ustekinumab已经证明对NSAIDs难治性SpA患者有效。我们在此报告一例伴有SpA的克罗恩病,作为肠外表现,其中ustekinumab被证明非常有效,不仅可以缓解关节炎,还可以对抗皮肤表现和巩膜炎。只有少数研究记录了ustekinumab对与IBD相关的SpA的治疗效果;因此,其功效尚不清楚。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.80
自引率
0.00%
发文量
34
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信